Triple

T4784926
Position Surface form Disambiguated ID Type / Status
Subject REGN-EB3 E106452 entity
Predicate hasComponent P35 FINISHED
Object maftivimab
Maftivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
 E468964 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: maftivimab | Statement: [REGN-EB3, hasComponent, maftivimab]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: maftivimab
Context triple: [REGN-EB3, hasComponent, maftivimab]
  • A. Biktarvy
    Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
  • B. velpatasvir
    Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
  • C. Novafora
    Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
  • D. faricimab
    Faricimab is a bispecific monoclonal antibody used to treat neovascular eye diseases such as wet age-related macular degeneration and diabetic macular edema by targeting both VEGF-A and Ang-2 pathways.
  • E. Kymab
    Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: maftivimab
Triple: [REGN-EB3, hasComponent, maftivimab]
Generated description
Maftivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: maftivimab
Target entity description: Maftivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
  • A. Biktarvy
    Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
  • B. velpatasvir
    Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
  • C. Novafora
    Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
  • D. faricimab
    Faricimab is a bispecific monoclonal antibody used to treat neovascular eye diseases such as wet age-related macular degeneration and diabetic macular edema by targeting both VEGF-A and Ang-2 pathways.
  • E. Kymab
    Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69bd43f4a9588190bf73e20bc27c03cc completed March 20, 2026, 12:56 p.m.
NER Named-entity recognition batch_69bd65ae49ec81908f16248d22d1155f completed March 20, 2026, 3:20 p.m.
NED1 Entity disambiguation (via context triple) batch_69be43dbdec88190817845e7930a18f6 completed March 21, 2026, 7:08 a.m.
NEDg Description generation batch_69be447c21d48190ab57c8761e733ff4 completed March 21, 2026, 7:10 a.m.
NED2 Entity disambiguation (via description) batch_69be45f5ebec8190b62c428b465d1bd9 completed March 21, 2026, 7:17 a.m.
Created at: March 20, 2026, 1:22 p.m.